BRAF inhibitor induced verrucal keratosis

American Journal of Dermatopathology

Volumn 36, Issue 2, 2014, Pages 192-

  Anforth, Rachael ^a,b   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KERATOACANTHOMA; KERATOSIS; MALE; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SKIN DISEASES;

EID: 84894528407     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182858142     Document Type: Letter

References (3)

1. Harvey NT, Millward M, Wood BA. Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol. 2012; 34:822-826
2. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153-1160
3. Anforth R, Tembe V, Blumetti T, et al. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012; 25:569-572